AZN - AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk Reports Mixed Q3 Earnings | Benzinga
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, up 4% Y/Y (+9% on constant currency). On the ADR basis, core earnings are $0.86 per share, beating the consensus of $0.84.
Total revenue in the quarter was $11.49 billion, up 5% (+6% CER), missing the analyst estimates of $11.66 billion.
Excluding COVID-19 medicines, Q3 2023 Total Revenue increased by 12% (13% at CER).
Guidance: AstraZeneca raised its annual earnings forecast and expects core earnings per share to increase by a ...